These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 11411125)

  • 1. [Current status and future prospect of prostacyclin therapy for pulmonary hypertension--intravenous, subcutaneous, inhaled and oral PGI2 derivatives].
    Saji T; Nakayama T; Ishikita T; Matsuura H
    Nihon Rinsho; 2001 Jun; 59(6):1132-8. PubMed ID: 11411125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
    Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
    Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension].
    Saji T; Ozawa Y; Nakayama T; Matsuura H; Hashiguchi R; Matsuo N; Muto H; Yamazaki J; Morishita T; Saito T
    J Cardiol; 1996 Apr; 27(4):197-205. PubMed ID: 8642506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostanoid therapy for pulmonary arterial hypertension.
    Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
    Nakayama T; Ishikita T; Matsuura H; Saji T
    J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension.
    Stricker H; Domenighetti G; Fiori G; Mombelli G
    Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure.
    Reddy MT; Patel H; Ventura HO
    Congest Heart Fail; 2008; 14(5):285-6. PubMed ID: 18983294
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement.
    Fattouch K; Sbraga F; Bianco G; Speziale G; Gucciardo M; Sampognaro R; Ruvolo G
    J Card Surg; 2005; 20(2):171-6. PubMed ID: 15725144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.
    Opitz CF; Wensel R; Bettmann M; Schaffarczyk R; Linscheid M; Hetzer R; Ewert R
    Eur Heart J; 2003 Feb; 24(4):356-65. PubMed ID: 12581683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
    Osvaldo Cáneva J; Ossés JM
    Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled prostacyclin following surgical repair of congenital heart disease--a pilot study.
    Carroll CL; Backer CL; Mavroudis C; Cook K; Goodman DM
    J Card Surg; 2005; 20(5):436-9. PubMed ID: 16153274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
    Gomberg-Maitland M; Preston IR
    Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
    Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.
    Hoeper MM; Schwarze M; Ehlerding S; Adler-Schuermeyer A; Spiekerkoetter E; Niedermeyer J; Hamm M; Fabel H
    N Engl J Med; 2000 Jun; 342(25):1866-70. PubMed ID: 10861321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives.
    Bratel T; Lagerstrand L; Brodin LA; Nowak J; Randmaa I
    Chest; 2005 Dec; 128(6 Suppl):615S-616S. PubMed ID: 16373868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.